Foghorn Therapeutics vs Zymeworks
Zymeworks is the larger business, with $106m of revenue in fiscal 2025 against $30.9m for Foghorn Therapeutics (3.4 times as much). Zymeworks grew faster (38.9% against 36.8%). Zymeworks kept more of each dollar of sales as profit: a net margin of -76.6% against -240.3%.
| Latest fiscal year | Foghorn TherapeuticsFHTX, 2025 | ZymeworksZYME, 2025 |
|---|---|---|
| Revenue | $30.9m | $106m |
| Revenue growth | 36.8% | 38.9% |
| Net income | −$74.3m | −$81.1m |
| Operating margin | -279.5% | -87.3% |
| Net margin | -240.3% | -76.6% |
| Return on equity | — | -26.7% |
| Free cash flow | −$86.1m | −$34.5m |
| Cash | $80.9m | $41.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $41.7m |
| Employees | 106 | 264 |
| Market value | $125m | $2.07bn |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 11 sales |